CClinicalTrials.gg
CompletedNCT03457571Updated Mar 7, 2018

Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome

An observational study in Inflammatory Bowel Diseases, Restless Legs Syndrome and Iron-deficiency, sponsored by Charite University, Berlin, Germany. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by Charite University, Berlin, Germany · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
353
Ages
18 Years and older
Sex
All
01

Study summary

Patients with inflammatory bowel disease, such as Crohn´s disease or ulcerative colitis, have recurring episodes of abdominal pain, diarrhea and loss of weight. Besides this other clinical symptoms are possible e.g. deficiency syndromes such as iron deficiency. Iron deficiency usually attended by symptoms like hair loss, pale skin, loss of concentration or fatigue. In some cases iron deficiency can lead to neurological manifestations such as restless-legs-syndrome (RLS). Restless legs syndrome is a neurological disorders which is accompanied by substantial urge to move legs or other parts of the body and unpleasant sensations.

Aim of this study is to to investigate the prevalence of RLS in patients with inflammatory bowel disease and furthermore evaluate the effect of iron supplementation in patients with iron deficiency and concomitant RLS.

Read the detailed description

Restless legs syndrome (RLS) is a common neurological disease significantly impacting live quality. Two recent studies from North America and Japan revealed a surprisingly high prevalence for RLS in Crohn´s disease and ulcerative colitis (30% and 21%, respectively). The underlying cause for this high prevalence remains elusive at this point.

To address this gap, a cohort of 353 IBD patients from a tertiary IBD centre was prospectively evaluated by our IBD team as well as by the colleagues from neurology. IBD patients (age ≥ 18 years) presenting at our IBD outpatient clinic (tertiary referral center) between February 2014 and February 2015 were prospectively recruited for the study after written consent. The study was approved (16 January 2014) by the ethics committee of the Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin (reference EA4/132/13). Patients were screened for symptoms of iron deficiency (ID) and RLS by a self-developed questionnaire and explored for RLS symptoms by a gastroenterologist. When at least one symptom of RLS was present, patients were referred to a neurologist for RLS or differential diagnosis.

Additionally patients with RLS symptoms were screened for iron-, folic acid- and vitamin B12-deficiency. If a deficiency was detected, patients were substituted. In patients with deficiencies, follow-up visits were scheduled at week 4 and 11 after starting supplementation. Follow-up visits were conducted by the neurologist and the IRLS was performed in all patients at each visit.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with inflammatory bowel disease in IBD outpatient clinic (tertiary referral center) in Germany

Inclusion criteria

  • Written consent
  • Age > 18
  • Inflammatory bowel disease

Exclusion criteria

Exclusion Criteria:

  • \<18 years
  • No written consent
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
353 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Prevalence of RLS in IBD

    Time frame: 1 year

Secondary outcomes

  1. Prevalence of clinically relevant RLS in IBD

    Time frame: 1 year

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Becker J, Berger F, Schindlbeck KA, Poddubnyy D, Koch PM, Preiss JC, Siegmund B, Marzinzik F, Maul J. Restless legs syndrome is a relevant comorbidity in patients with inflammatory bowel disease. Int J Colorectal Dis. 2018 Jul;33(7):955-962. doi: 10.1007/s00384-018-3032-8. Epub 2018 Apr 3. PubMed 29610943 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03457571
Lead sponsor
Charite University, Berlin, Germany
Responsible party
Janek Becker (MD, Charite University, Berlin, Germany) — Principal investigator
First posted
Mar 7, 2018
Start date
Feb 1, 2014
Primary completion
Feb 28, 2015
Completion
Apr 30, 2015
Last update
Mar 7, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion